Your browser doesn't support javascript.
loading
Highlights from the 2024 ASCO Genitourinary Symposium: focus on urothelial and prostate cancer.
Strusi, Alessandro; Pinterpe, Giada; Ciccarese, Chiara; Pedone, Romina Rose; Sarcina, Michele; Sardaro, Valeria; Belletto, Rachele; Totaro, Angelo; Racioppi, Marco; Berardi, Rossana; Tortora, Giampaolo; Iacovelli, Roberto.
Afiliación
  • Strusi A; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Pinterpe G; Clinica Oncologica e Centro Regionale di Genetica Oncologica, AOU delle Marche, Ancona, Italy.
  • Ciccarese C; Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Pedone RR; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Sarcina M; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Sardaro V; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Belletto R; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Totaro A; Urology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Racioppi M; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
  • Berardi R; Urology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
  • Tortora G; Clinica Oncologica e Centro Regionale di Genetica Oncologica, AOU delle Marche, Ancona, Italy.
  • Iacovelli R; Facoltà di Medicina e Chirurgia, Università Cattolica del Sacro Cuore, Rome, Italy.
Expert Rev Anticancer Ther ; 24(8): 661-664, 2024 Aug.
Article en En | MEDLINE | ID: mdl-38932631
ABSTRACT
The 2024 ASCO Genitourinary Cancer Symposium, this year celebrating the 20th anniversary, delved into key advancements in urothelial carcinoma (UC) and prostate cancer (PC). For UC, insights emerged from adjuvant pembrolizumab for muscle-invasive urothelial carcinoma, and from the efficacy of the EV-302 study of enfortumab vedotin +pembrolizumab in the metastatic setting. In PC, adjuvant therapy with high-dose radiotherapy schedules plus long-t erm ADT was explored. In metastatic castration-resistant PC, highlights included a novel combo (cabozantinib+atezolizumab) for poor prognosis patients; confirmed benefits of ARSI+PARPi in BRCA-mutated patients; and safety considerations for ARSI treatments. The symposium continued its role as an indispensable platform for shaping specialized oncological care.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Límite: Humans / Male Idioma: En Revista: Expert Rev Anticancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Italia
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Próstata Límite: Humans / Male Idioma: En Revista: Expert Rev Anticancer Ther Asunto de la revista: NEOPLASIAS / TERAPEUTICA Año: 2024 Tipo del documento: Article País de afiliación: Italia